FindTrial
Sign In

Comparison of visual outcomes of SMILE surgery performed for high myopic astigmatism using a software with Visumax 800(a new laser machine) versus manual technique used with Visumax 500(another laser machine)

Comparison of visual and refractive outcomes of SMILE performed for high myopic astigmatism[greater than or equals to 1.5 D( /=1.5D)] using the OcuLign software with Visumax 800 versus manual cyclotorsion compensation with Visumax 500

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/040417
Enrollment
100
Registered
2022-02-18
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H522- Astigmatism

Interventions

Intervention1: Astigmatism treatment by Visumax 800 using OcuLign Software: Visual and Refractive outcomes after using OcuLign software in Visumax800 for astigmatism treatment Control Intervention1: A

Sponsors

CARL ZEISS MEDITEC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)SE between -1D to -10D 2)Astigmatism upto -5D

Exclusion criteria

Exclusion criteria: 1)keratoconus 2)Pellucid marginal degeneration or suspect cornea 3)severe dry eye or meibomian gland disease 4)glaucoma 5)retinal diseases 6)pregnancy 7)patients on immunosupressants 8)patients with unassured follow up

Design outcomes

Primary

MeasureTime frame
To evaluate the outcomes of astigmatism correction with the use of OcuLign software in Visumax800Timepoint: 1)post-op day1 2)post-op day7 3)post-op day180—

Secondary

MeasureTime frame
To evaluate safety and efficacy of OcuLign software in Visumax 800Timepoint: 1)post day1 2)post-op day7 3_post-op day 180—

Countries

India

Contacts

Public ContactDr Hemali Bhavsar

Nethradhama superspeciality eye hospital

brar_sheetal@yahoo.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026